Article -> Article Details
Title | Cardiac Biomarkers Market size, share and market intelligence forecast to 2025 |
---|---|
Category | Fitness Health --> Health Insurance |
Meta Keywords | Cardiac Biomarkers Market |
Owner | vinit |
Description | |
Cardiac biomarkers are often referred to as cardiac markers.
The cardiac biomarkers (endogens, including enzymes, hormones, and proteins)
are released into the blood if the heart is damaged or stressed. Generally,
they are used to treat heart attack and acute coronary syndrome (ACS) or
disorders associated with insufficient blood flow to the core According to Market Research Future (MRFR), Cardiac
Biomarkers Market is expected to cross USD 4236.02 Million
2025 at a CAGR of 16.36% by 2025 (forecast period). The research
report serves as insight and knowledge repository for all market aspects
including, regional markets, technology, types, and applications. There are a number of factors that impact the growth of the
cardiac biomarkers market. Some of the key factors include a rise in demand for
diagnostic and testing of various cardiovascular diseases, development and
advancement in cardiac biomarkers, and growth in the patient population
suffering from cardiovascular diseases. Other key growth drivers include the rise in the number of
new cardiovascular cases diagnosed each year and the increase in demand for
disease-specific treatment in which cardiac biomarkers are used. The increasing
prevalence of cardiovascular diseases is expected to boost the cardiac
biomarkers market during the forecast period. Market Dynamics There are a variety of factors that affect the development
of the demand for cardiac biomarkers. Some of the main factors include growing
demand for the diagnosis and testing of various cardiovascular diseases, the
production and advancement of cardiac biomarkers and the growth of the patient
population suffering from cardiovascular disease. Other primary growth factors
include a rise in the number of new cardiovascular cases diagnosed per year and
an increase in demand for disease-specific care in which cardiac biomarkers are
used. Increased prevalence of the cardiovascular disease is projected to fuel
the demand for cardiac biomarkers during the forecast period. Approximately
17.7 million people die each year from cardiovascular diseases (CVDs),
according to the World Health Organization, and it is estimated to be the cause
of 31% of the total deaths worldwide. About 80% of all deaths from CVDs are
attributed to heart attacks and strokes. Nonetheless, the demand for cardiac
biomarkers is experiencing constraints due to the emergence of other methods
for cardiovascular disease diagnosis, along with high procedural costs, lack of
full proof assurance, and strong competition among existing players. Segmentation Based on type, the cardiac biomarkers market can be segmented
into Myocardial muscle Creatine Kinase (CK-MB), troponins (T and I),
myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP,
ischemia-modified albumin (IMA), and others. Owing to its prodigious
sensitivity and ability to reliably diagnose the heart events of an acute
coronary syndrome (ACS), Troponins I and T are the leading revenue-generating
segment in the global cardiac biomarkers market. The location of testing is further segmented into point of
care testing and laboratory testing. The point of care testing is projected to
see steady growth in the forecast period due to its increasing popularity. The
laboratory testing segment dominated the global market for cardiac biomarkers.
Increased demand for cardiovascular disease diagnostics is increasing the
revenue of this segment. Key Players Key companies operating in the global cardiac biomarkers market are Abbott Laboratories, ACS Biomarker (The Netherlands), BD (Becton, Dickinson, and Company) (US), bioMĂ©rieux SA (France), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), Hoffmann-La Roche Ltd (Switzerland), Johnson and Johnson (US), Quidel Corporation (US), Randox Laboratories Limited (UK), Siemens AG (Germany), Thermo Fisher Scientific, Inc. (the US), Trivitron Healthcare Pvt. Ltd. (India), and Novartis (Switzerland) |